2025-01-15 – Press Releases – www.prnewswire.com
AT03-65 is the first program utilizing AxcynDOT, a proprietary payload with a differentiated mechanism of action, to enter clinical development SINGAPORE, Jan. 15, 2025 /PRNewswire/ — Axcynsis Therapeutics Pte Ltd (“Axcynsis”), a privately held biopharmaceutical company specialized in…